Advanced Enzyme Technologies Ltd
Advanced Enzyme Technologies Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
The management aspires to achieve at least double-digit growth but is cautious due to recent market conditions; currently expecting single-digit growth for FY '25 with hopes to improve in FY '26. - Significant growth seen in industrial bioprocessing and specialized manufacturing segments, with optimism about sustaining these growth rates driven by new product developments and expanding markets. - Focus on expanding sales force, especially in the U.S. The company aspires to at least two-digit growth but is currently cautious, expecting mainly single-digit growth in the near term (Page 13). - Signs of recovery are seen, especially in the U.S.
From Advanced Enzyme Technologies Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The management aspires to achieve at least double-digit growth but is cautious due to recent market conditions; currently expecting single-digit growth for FY '25 with hopes to improve in FY '26.
- Significant growth seen in industrial bioprocessing and specialized manufacturing segments, with optimism about sustaining these growth rates driven by new product developments and expanding markets.
- Focus on expanding sales force, especially in the U.S. and Europe, to capitalize on brand recognition and inbound sales opportunities.
- Continued emphasis on innovations in gut health, protein powders, pet supplements, and probiotics as integrated parts of their enzyme product portfolio for future revenue growth.
- Probiotics market expansion expected to contribute to growth but integrated within enzyme sales rather than as a separate category.
2 more points from Advanced Enzyme Technologies Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company plans to commission the new Nashik R&D facility by the end of calendar year 2025, which will be three times bigger than the current setup. (Page 14)
- They are in the process of recruiting talented personnel to support this expansion. (Page 14)
- Capacity utilization is currently at 55-60%; they plan to expand manufacturing capacity upon reaching 80% utilization. (Page 15)
- There is ongoing investment in new product development, with 5-6 new molecules added each year and expectations to commercialize some biocatalyst molecules in the near future. (Pages 14-15)
2 more points from Advanced Enzyme Technologies Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected orderbook or pending orders for Advanced Enzyme Technologies Limited.
- The company discusses growth prospects, new product commercialization, and market dynamics but no specific details on orderbook size.
- Mukund Kabra and other executives focus on discussing sales trends, capacity utilization (~55-60%), and organic growth challenges.
- They highlight strategic acquisitions, R&D developments, and expanding market presence, especially in the U.S. nutraceutical sector.
2 more points from Advanced Enzyme Technologies Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹203 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Advanced Enzyme Technologies Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
Arthneeti Pro · Annual
Advanced Enzyme Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Advanced Enzyme Technologies Ltd Q3 FY25 results?
The management aspires to achieve at least double-digit growth but is cautious due to recent market conditions; currently expecting single-digit growth for FY '25 with hopes to improve in FY '26. - Significant growth seen in industrial bioprocessing and specialized manufacturing segments, with optimism about sustaining these growth rates driven by new product developments and expanding markets. - Focus on expanding sales force, especially in the U.S. The company aspires to at least two-digit growth but is currently cautious, expecting mainly single-digit growth in the near term (Page 13). - Signs of recovery are seen, especially in the U.S.
What is Advanced Enzyme Technologies Ltd share price analysis?
Advanced Enzyme Technologies Ltd currently shows a neutral. The stock trades at a P/E of 24.0 with a market cap of ₹3,726 Cr. Investors should review the full earnings analysis for detailed insights.
Is Advanced Enzyme Technologies Ltd planning capital expenditure?
The company plans to commission the new Nashik R&D facility by the end of calendar year 2025, which will be three times bigger than the current setup.
Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.